These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 36835121)

  • 1. The Relationship between Iron and LRRK2 in a 6-OHDA-Induced Parkinson's Disease Model.
    Jia R; Liu Y; Shuai K; Zhou C; Chen L; Zhu L; Wu XM
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity.
    Nguyen APT; Tsika E; Kelly K; Levine N; Chen X; West AB; Boularand S; Barneoud P; Moore DJ
    Proc Natl Acad Sci U S A; 2020 Jul; 117(29):17296-17307. PubMed ID: 32631998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective expression of Parkinson's disease-related Leucine-rich repeat kinase 2 G2019S missense mutation in midbrain dopaminergic neurons impairs dopamine release and dopaminergic gene expression.
    Liu G; Sgobio C; Gu X; Sun L; Lin X; Yu J; Parisiadou L; Xie C; Sastry N; Ding J; Lohr KM; Miller GW; Mateo Y; Lovinger DM; Cai H
    Hum Mol Genet; 2015 Sep; 24(18):5299-312. PubMed ID: 26123485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit function.
    Sloan M; Alegre-Abarrategui J; Potgieter D; Kaufmann AK; Exley R; Deltheil T; Threlfell S; Connor-Robson N; Brimblecombe K; Wallings R; Cioroch M; Bannerman DM; Bolam JP; Magill PJ; Cragg SJ; Dodson PD; Wade-Martins R
    Hum Mol Genet; 2016 Mar; 25(5):951-63. PubMed ID: 26744332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD.
    Chen CY; Weng YH; Chien KY; Lin KJ; Yeh TH; Cheng YP; Lu CS; Wang HL
    Cell Death Differ; 2012 Oct; 19(10):1623-33. PubMed ID: 22539006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphorylation of amyloid precursor protein by mutant LRRK2 promotes AICD activity and neurotoxicity in Parkinson's disease.
    Chen ZC; Zhang W; Chua LL; Chai C; Li R; Lin L; Cao Z; Angeles DC; Stanton LW; Peng JH; Zhou ZD; Lim KL; Zeng L; Tan EK
    Sci Signal; 2017 Jul; 10(488):. PubMed ID: 28720718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parkinson's Disease-Associated LRRK2 Hyperactive Kinase Mutant Disrupts Synaptic Vesicle Trafficking in Ventral Midbrain Neurons.
    Pan PY; Li X; Wang J; Powell J; Wang Q; Zhang Y; Chen Z; Wicinski B; Hof P; Ryan TA; Yue Z
    J Neurosci; 2017 Nov; 37(47):11366-11376. PubMed ID: 29054882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a physiologically relevant and easily scalable LUHMES cell-based model of G2019S LRRK2-driven Parkinson's disease.
    Calamini B; Geyer N; Huss-Braun N; Bernhardt A; Harsany V; Rival P; Cindhuchao M; Hoffmann D; Gratzer S
    Dis Model Mech; 2021 Jun; 14(6):. PubMed ID: 34114604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptake.
    Zhou H; Huang C; Tong J; Hong WC; Liu YJ; Xia XG
    Int J Biol Sci; 2011; 7(6):753-61. PubMed ID: 21698001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dysregulated phosphorylation of Rab GTPases by LRRK2 induces neurodegeneration.
    Jeong GR; Jang EH; Bae JR; Jun S; Kang HC; Park CH; Shin JH; Yamamoto Y; Tanaka-Yamamoto K; Dawson VL; Dawson TM; Hur EM; Lee BD
    Mol Neurodegener; 2018 Feb; 13(1):8. PubMed ID: 29439717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson's disease.
    Tozzi A; Tantucci M; Marchi S; Mazzocchetti P; Morari M; Pinton P; Mancini A; Calabresi P
    Cell Death Dis; 2018 Feb; 9(2):204. PubMed ID: 29434188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extracellular Zn
    Tamano H; Nishio R; Morioka H; Takeda A
    Mol Neurobiol; 2019 Jan; 56(1):435-443. PubMed ID: 29705946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LRRK2 phosphorylation of auxilin mediates synaptic defects in dopaminergic neurons from patients with Parkinson's disease.
    Nguyen M; Krainc D
    Proc Natl Acad Sci U S A; 2018 May; 115(21):5576-5581. PubMed ID: 29735704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The industrial solvent trichloroethylene induces LRRK2 kinase activity and dopaminergic neurodegeneration in a rat model of Parkinson's disease.
    De Miranda BR; Castro SL; Rocha EM; Bodle CR; Johnson KE; Greenamyre JT
    Neurobiol Dis; 2021 Jun; 153():105312. PubMed ID: 33636387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LRRK2 G2019S and Parkinson's disease: insight from Neuroinflammation.
    Yao XY; Guan LN; Chen Q; Ren C
    Postgrad Med J; 2023 Dec; 100(1179):4-11. PubMed ID: 37777187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The C-terminal domain of LRRK2 with the G2019S mutation is sufficient to produce neurodegeneration of dopaminergic neurons in vivo.
    Cresto N; Gaillard MC; Gardier C; Gubinelli F; Diguet E; Bellet D; Legroux L; Mitja J; Auregan G; Guillermier M; Josephine C; Jan C; Dufour N; Joliot A; Hantraye P; Bonvento G; Déglon N; Bemelmans AP; Cambon K; Liot G; Brouillet E
    Neurobiol Dis; 2020 Feb; 134():104614. PubMed ID: 31605779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upregulation of the p53-p21 pathway by G2019S LRRK2 contributes to the cellular senescence and accumulation of α-synuclein.
    Ho DH; Seol W; Son I
    Cell Cycle; 2019 Feb; 18(4):467-475. PubMed ID: 30712480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In Vitro CRISPR/Cas9-Directed Gene Editing to Model LRRK2 G2019S Parkinson's Disease in Common Marmosets.
    Vermilyea SC; Babinski A; Tran N; To S; Guthrie S; Kluss JH; Schmidt JK; Wiepz GJ; Meyer MG; Murphy ME; Cookson MR; Emborg ME; Golos TG
    Sci Rep; 2020 Feb; 10(1):3447. PubMed ID: 32103062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dietary Amino Acids Impact LRRK2-Induced Neurodegeneration in Parkinson's Disease Models.
    Chittoor-Vinod VG; Villalobos-Cantor S; Roshak H; Shea K; Abalde-Atristain L; Martin I
    J Neurosci; 2020 Aug; 40(32):6234-6249. PubMed ID: 32605938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of inducible leucine-rich repeat kinase 2 (LRRK2) cell lines for therapeutics development in Parkinson's disease.
    Huang L; Shimoji M; Wang J; Shah S; Kamila S; Biehl ER; Lim S; Chang A; Maguire-Zeiss KA; Su X; Federoff HJ
    Neurotherapeutics; 2013 Oct; 10(4):840-51. PubMed ID: 23963789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.